THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 425

Session of 2019

INTRODUCED BY STEPHENS, BIZZARRO, ROTHMAN, HENNESSEY, BURNS, MILLARD, SCHMITT, KORTZ, DiGIROLAMO, LONGIETTI, McNEILL, RYAN, SCHLEGEL CULVER, HILL-EVANS, KINSEY, YOUNGBLOOD, CALTAGIRONE, READSHAW AND MOUL, JUNE 25, 2019

INTRODUCED AS NONCONTROVERSIAL RESOLUTION UNDER RULE 35, JUNE 25, 2019

A RESOLUTION

- 1 Recognizing the month of June 2019 as "National Myasthenia Gravis Awareness Month" in Pennsylvania.
- 3 WHEREAS, Myasthenia gravis is a chronic autoimmune
- 4 neuromuscular disorder that causes weakness in the skeletal
- 5 muscles responsible for moving the arms and legs and for
- 6 breathing; and
- 7 WHEREAS, Myasthenia gravis is caused by an error in the
- 8 transmission of nerve impulses to the muscles that prompts
- 9 weakness in the different muscle groups and can be fatal without
- 10 specialized care; and
- 11 WHEREAS, Myasthenia gravis causes antibodies to block, alter
- 12 or destroy the receptors that release a neurotransmitter called
- 13 acetylcholine; and
- 14 WHEREAS, Acetylcholine is necessary to activate the muscle
- 15 and cause muscle contractions; and
- 16 WHEREAS, The symptoms of myasthenia gravis include drooping

- 1 of one or both eyelids, blurred vision, change in facial
- 2 expression, difficulty swallowing, shortness of breath, impaired
- 3 speech and weakness in the arms, hands, fingers, legs or neck;
- 4 and
- 5 WHEREAS, The distinctive symptom of myasthenia gravis is
- 6 muscle weakness that worsens after periods of activity and
- 7 improves with periods of rest; and
- 8 WHEREAS, Although myasthenia gravis affects men and women
- 9 across all racial and ethnic groups, the disorder most commonly
- 10 impacts young adult women under 40 years of age or older men
- 11 over 60 years of age; and
- 12 WHEREAS, Even though myasthenia gravis can generally be
- 13 controlled, there are times during a myasthenic crisis when
- 14 emergency medical treatment is necessary and muscle weakness
- 15 requires a ventilator; and
- 16 WHEREAS, The National Institutes of Health and the National
- 17 Institute of Neurological Disorders and Stroke (NINDS) seek
- 18 greater understanding about the structure and function of the
- 19 neuromuscular junction that is impacted by myasthenia gravis;
- 20 and
- 21 WHEREAS, Findings from a recent NINDS-supported study yielded
- 22 conclusive evidence about the benefits of surgery for
- 23 individuals suffering from myasthenia gravis who do not have
- 24 thymoma; and
- 25 WHEREAS, Researchers are exploring better ways to treat
- 26 myasthenia gravis by developing new tools to better diagnose
- 27 individuals with undetectable antibodies and potential
- 28 biomarkers; therefore be it
- 29 RESOLVED, That the House of Representatives recognize the
- 30 month of June 2019 as "National Myasthenia Gravis Awareness

1 Month" in Pennsylvania.